Ory B - Search Results

1

Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice.

Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F. Ory B, et al. Cancer. 2005 Dec 1;104(11):2522-9. doi: 10.1002/cncr.21530. Cancer. 2005. PMID: 16270320 Free article.

2

Tracking Targets of Dynamic Super-Enhancers in Vitro to Better Characterize Osteoclastogenesis and to Evaluate the Effect of Diuron on the Maturation of Human Bone Cells.

Tesfaye RA, Lavaud M, Charrier C, Brounais-Le Royer B, Cartron PF, Verrecchia F, Baud'huin M, Lamoureux F, Georges S, Ory B. Tesfaye RA, et al. Among authors: ory b. Environ Health Perspect. 2023 Jun;131(6):67007. doi: 10.1289/EHP11690. Epub 2023 Jun 12. Environ Health Perspect. 2023. PMID: 37307168 Free PMC article.

3

Super-enhancers: drivers of cells' identities and cells' debacles.

Lavaud M, Tesfaye R, Lassous L, Brounais B, Baud'huin M, Verrecchia F, Lamoureux F, Georges S, Ory B. Lavaud M, et al. Among authors: ory b. Epigenomics. 2024 Apr 8;16(9):681-700. doi: 10.2217/epi-2023-0409. Online ahead of print. Epigenomics. 2024. PMID: 38587919 Review.

4

Bisphosphonates: new therapeutic agents for the treatment of bone tumors.

Heymann D, Ory B, Gouin F, Green JR, Rédini F. Heymann D, et al. Among authors: ory b. Trends Mol Med. 2004 Jul;10(7):337-43. doi: 10.1016/j.molmed.2004.05.007. Trends Mol Med. 2004. PMID: 15242682 Review.

5

Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma.

Heymann D, Ory B, Blanchard F, Heymann MF, Coipeau P, Charrier C, Couillaud S, Thiery JP, Gouin F, Redini F. Heymann D, et al. Among authors: ory b. Bone. 2005 Jul;37(1):74-86. doi: 10.1016/j.bone.2005.02.020. Bone. 2005. PMID: 15894525

6

Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival.

Gouin F, Ory B, Rédini F, Heymann D. Gouin F, et al. Among authors: ory b. Int J Cancer. 2006 Sep 1;119(5):980-4. doi: 10.1002/ijc.21951. Int J Cancer. 2006. PMID: 16570273

7

Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status.

Ory B, Blanchard F, Battaglia S, Gouin F, Rédini F, Heymann D. Ory B, et al. Mol Pharmacol. 2007 Jan;71(1):333-43. doi: 10.1124/mol.106.028837. Epub 2006 Oct 18. Mol Pharmacol. 2007. PMID: 17050806

8

mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours.

Ory B, Moriceau G, Redini F, Heymann D. Ory B, et al. Curr Med Chem. 2007;14(13):1381-7. doi: 10.2174/092986707780831159. Curr Med Chem. 2007. PMID: 17584050 Review.

9

Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid.

Lamoureux F, Ory B, Battaglia S, Pilet P, Heymann MF, Gouin F, Duteille F, Heymann D, Redini F. Lamoureux F, et al. Among authors: ory b. Int J Cancer. 2008 Feb 15;122(4):751-60. doi: 10.1002/ijc.23187. Int J Cancer. 2008. PMID: 17960623

10

Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells.

Ory B, Moriceau G, Trichet V, Blanchard F, Berreur M, Rédini F, Rogers M, Heymann D. Ory B, et al. J Cell Mol Med. 2008 Jun;12(3):928-41. doi: 10.1111/j.1582-4934.2008.00141.x. J Cell Mol Med. 2008. PMID: 18494934 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64 results

Search Page

Filters